Cervical cancer is the fourth most common cancer worldwide, with over 600,000 new cases annually and approximately 350,000 cancer-related deaths per year. The disease burden is disproportionately distributed, with cancer-related mortality ranging from 5.2 deaths per 100,000 individuals in highly-developed countries, to 12.4 deaths per 100,000 in less-developed countries. This article is a review of the current screening recommendations and potential future recommendations.

Background/Objectives: After several decades of using titrated paclitaxel infusions, our institution adopted non-titrated infusions in April 2023 to streamline infusion workflows. We aimed to evaluate whether this alteration in infusion was associated with a higher incidence of HSRs. Methods: This was a retrospective cohort study of patients receiving paclitaxel with titration versus non-titration from April 2022 through November 2023. Patients diagnosed with gynecologic cancers who presented for their first or second paclitaxel lifetime infusions were included. Results: A total of 150 patients were included in this study, each with one or two infusions, for a total of 282 infusion visits. There were 176 infusions performed with titrated paclitaxel (62.4%), and 106 infusions performed with non-titrated paclitaxel dose (37.6%). HSRs occurred in 20.8% of the non-titrated paclitaxel infusions and in 11.9% of titrated paclitaxel infusions (RR 1.73 (95% CI 1.006–3.006), p = 0.047). Additionally, when stratifying by first- or second-visit infusions, the HSR rate increased significantly for non-titrated infusions to 22.4% during the second visit, while there was a decrease to 8.4% for titrated infusions (RR 2.66 (95% CI 1.105–6.413), p = 0.029). Non-titrated infusion reactions were associated with higher grades of reaction. Conclusions: HSRs occurred more frequently with non-titrated infusions, particularly during the second administration, suggesting that eliminating titration may increase hypersensitivity risk. These findings support a prospective evaluation of titration rates to further refine paclitaxel administration.

Introduction: Metastasis of pancreatic adenocarcinoma to the ovaries is uncommon and can clinically present similarly to primary ovarian disease, presenting challenges for diagnosis. Immunohistochemical staining is typically useful in distinguishing ovarian primaries from ovarian metastasis. A newer and rarer variant of pancreatic adenocarcinoma, that with intestinal-type differentiation, has not previously been reported as metastasizing to the ovary. Its diagnosis is particularly difficult due to the overlap in staining patterns with primary ovarian neoplasms. Case Report: This case report presents the case of a 60-year-old female who presented with non-specific abdominal symptoms and was found to have a large adnexal mass. Imaging showed additional lesions in the peritoneum, pancreas, and liver. She underwent biopsy with morphology and immunohistochemical staining consistent with pancreatic ductal adenocarcinoma with intestinal-type differentiation. She was started on FOLFIRINOX therapy but ultimately opted to pursue comfort care due to disease progression. Conclusion: Although rare, with this being the first report of this disease course to our knowledge, clinicians should be aware of this possibility, as it impacts choice of treatment.